Regulatory Ahead of ASCO data drop, AZ gets key Imfinzi approval PharmaphorumAstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease. Oncology Read full story Post navigation Previous: Medicare Advantage Out-of-Pocket Limits: Variation and TrendsNext: GSK’s Nucala secures NICE COPD endorsement Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
